Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

the company announced that the first study (Study 102) met its primary 48-week efficacy endpoint showing that Viread is non-inferior to Hepsera among patients with HBeAg-negative/anti-HBe positive (presumed pre-core mutant) chronic hepatitis B.

"The preliminary data observed in both Phase III trials evaluating Viread as a potential treatment option for chronic hepatitis B are very encouraging," said Franck Rousseau, MD, Vice President, Clinical Research, Gilead Sciences. "We look forward to reviewing these data with regulatory authorities and are working quickly to file a New Drug Application in the United States and Marketing Authorisation Application in Europe in the fourth quarter of this year."

The active ingredient in Viread, tenofovir DF, is currently the most prescribed molecule in the United States for combination HIV therapy. Viread received approval as an anti-HIV medication from the U.S. Food and Drug Administration (FDA) in October 2001 and from the European Commission in February 2002. Viread is not approved as a treatment for chronic hepatitis B, and data from this analysis have not been reviewed by the FDA.

Study Design

Study 103 is a multi-center, randomized, double-blind Phase III clinical trial that compares the efficacy, safety and tolerability of Viread and Hepsera over 48 weeks among patients with HBeAg-positive chronic hepatitis B. Two hundred and sixty-six patients were randomized in a 2:1 ratio to receive either Viread (300 mg once daily; n=176) or Hepsera (10 mg once daily; n=90).

About Viread (tenofovir disoproxil fumarate)

In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Viread should not be used in combination with the fixed-dose combination products Truvada(R) or Atripla(TM) because they already contain Viread.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported wit
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
(Date:8/27/2015)... 2015 Major pharmaceutical and medical device companies and ... in Philadelphia on Oct. 20, discussing ... Hagy of HB Litigation Conferences has announced. ... at http://litigationconferences.com/?p=31886 The program is co-chaired ... Mahoney and Michelle Hart Yeary of Dechert LLP. ...
(Date:8/27/2015)... Aug. 27, 2015  Mytrus, a technology and services company revolutionizing ... electronic informed consent has received approval for use by ... It is the first time e-Consent technology will be ... . Mytrus was also the first ... clinical trial by the U.S. Food and Drug Administration ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Services is pleased to announce the exciting addition of ... the new Manager of Minerals.  Dr. Al-Ammar brings with ... has over fourteen years of experience with ICP-MS and ... United States and Europe.  Additionally, Dr. Al-Ammar has seven ...
... 15, 2011 PPTA opposes New Jersey Assembly Bill 2003 ... 13 that imposes a new tax on therapies used to ... The Bleeding Disorders Treatment Fund by taxing the manufacturers of ... rebate. PPTA opposes any policy that would impose a tax ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2PPTA Opposes Tax on Blood Clotting Factor 2
(Date:8/27/2015)... Del. (PRWEB) , ... August 27, 2015 , ... Dr. ... will be the guest speaker at CURE® magazine’s 3rd Annual MPN Heroes™ recognition ... Dr. Arnold will be among hundreds of attendees honoring eight heroes who have made ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, ... Glushko, professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko ... her training and recovery. , With a focus on technology and comfort, Zensah® ...
(Date:8/27/2015)... ... August 27, 2015 , ... For the first time, Ninja® ... the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. These ... drink customization to a whole new level. This line of Nutri Ninja products ...
(Date:8/27/2015)... ... August 27, 2015 , ... Sunbelt® Bakery, maker of ... corn syrup, is changing the expectation of how protein bars should taste with the ... unlike any other protein bar on the market today. , The new Protein ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2
... FRANCISCO, March 26 We are excited ... partner for the,Parkinson,s Disease Foundation. Zoomedia,s initial ... Foundation current website, PDF.org and,the website of ... awareness initiative led by the Parkinson,s Disease ...
... March 27,caregivers at the Motion Picture & Television ... hope of preventing a future strike. More than,570 ... West, were,forced to authorize a strike after management ... the workers, proposals to increase staffing levels and,recruit ...
... global,outsource provider of clinical documentation technology and services, today,announced ... 31, 2007., Financial Highlights-Fourth Quarter of 2007, ... $48.6 million compared,with $51.4 million in the fourth quarter ... the fourth quarter of 2007 from the prior-year,period was ...
... Presbyterian/St. Luke,s,Hospital and Rocky Mountain Pediatric Hematology-Oncology are ... of the Children,s Oncology Group,(C.O.G.). C.O.G. is supported ... world,s largest cooperative childhood, adolescent and young adult,cancer ... States about 9,000 children are diagnosed with,cancer. Because ...
... potential stumbling block, experts say , , WEDNESDAY, March 26 (HealthDay ... help predict future cardiac problems, a new study shows, but ... would be worth the cost. , "It has been shown ... Bild, deputy director of the division of prevention and population ...
... March 26 Michael D. Farley has,joined ... office in Washington,DC as the organization,s Chief ... the Foundation,s overall organizational administration and,field development. ... health organizations, including serving most recently as ...
Cached Medicine News:Health News:Zoomedia Teams Up With The Parkinson's Disease Foundation 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:The Rocky Mountain Hospital for Children at Presbyterian/St. Luke's is now Member of the Children's Oncology Group 2Health News:Calcium Scans Help Predict Coronary Risk 2Health News:Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc. 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: